Harnessing PUMA's lethal potential: BCL-2 family dynamics and novel strategies to combat cancer recurrence
Moustafa A Mansour1, Mohamed Abdel-Fattah El-Salamoni2, Hamdi Nabawi Mostafa3
1Department of Neurosurgery, Nasser Institute for Research and Treatment, Cairo, Egypt.
Abstract:
Cancer cells often survive treatment by blocking the natural process of cell death, allowing them to return and grow again. The BCL-2 protein family plays a central role in this process, controlling whether a cell lives or dies. Among its members, the BH3-only proteins initiate the apoptotic cascade in response to cellular stress. PUMA (p53-upregulated modulator of apoptosis), a pro-apoptotic BH3-only protein, is the most potent of its subclass, binding all major anti-apoptotic BCL-2 family members (Bcl-xL, Bcl-2, Mcl-1, and Bcl-w) to counteract their inhibition of Bax and Bak. Upon activation, Bax/Bak form pores in the mitochondrial membrane, releasing apoptogenic factors such as cytochrome c, SMAC, and apoptosis-inducing factor, ultimately triggering caspase-mediated cell death. Due to its upstream role in apoptosis, PUMA deficiency or inhibition by anti-apoptotic proteins promotes cancer development and therapy resistance. Conversely, elevated PUMA expression sensitizes cancer cells to chemo- and radiotherapy. Accumulating evidence positions PUMA as a universal sensor of cell death stimuli and a promising therapeutic target in cancer. This article critically examines PUMA's regulation, function, and potential as a target for cancer treatment.
Insights
Cancer cells evade death by inhibiting apoptosis, but PUMA (p53-upregulated modulator of apoptosis) can trigger cell death. Enhancing PUMA expression may overcome cancer therapy resistance.
Area of Science:
- Molecular Biology
- Cell Biology
- Oncology
Background:
- Cancer cells evade apoptosis, a natural cell death process, contributing to treatment resistance and recurrence.
- The BCL-2 protein family regulates apoptosis; BH3-only proteins, like PUMA, initiate this process.
- PUMA (p53-upregulated modulator of apoptosis) is a potent pro-apoptotic protein that counteracts anti-apoptotic BCL-2 members.
Purpose of the Study:
- To examine the regulation and function of PUMA in apoptosis.
- To evaluate PUMA's potential as a therapeutic target in cancer treatment.
- To understand PUMA's role in cancer cell survival and therapy resistance.
Main Methods:
- Review of existing literature on PUMA's role in apoptosis.
- Analysis of PUMA's interactions with BCL-2 family proteins.
- Examination of PUMA's impact on cancer cell sensitivity to treatments.
Main Results:
- PUMA activates the mitochondrial apoptotic pathway by counteracting anti-apoptotic proteins.
- PUMA deficiency promotes cancer development and therapy resistance.
- Elevated PUMA expression sensitizes cancer cells to chemotherapy and radiotherapy.
Conclusions:
- PUMA is a critical regulator of apoptosis and a universal sensor of cell death stimuli.
- Targeting PUMA presents a promising strategy for overcoming cancer therapy resistance.
- Further research into PUMA's regulation and function can inform novel cancer treatments.
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:23Abnormal Proliferation
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:56Treatment Resistant Cancers